Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

- PMLiVE

Vertex scores FDA approval for CF triple therapy Trikafta

Decision comes only a few months after therapy was filed

Roche Basel Switzerland

Roche scores another FDA approval for Xofluza

Expands use to patients at high risk of flu-related complications

- PMLiVE

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Head-to-head trial with rival Eylea could boost sales

- PMLiVE

SMC approves Yescarta and Keytruda, rejects Perjeta

Cancer drugs lead the latest round of recommendations

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

- PMLiVE

Gilead claims FDA okay for Descovy as second PrEP option

Can now push new indication before generics dent franchise

- PMLiVE

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year

- PMLiVE

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

Could be an alternative treatment option to chemotherapy

It’s the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

Back on track after being turned down twice

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links